索拉非尼联合经动脉化疗栓塞治疗肝癌合并下腔静脉肿瘤血栓患者的长期生存:2例报告并文献复习。

Q Medicine

癌症 Pub Date : 2014-05-01 Epub Date: 2013-12-11 DOI:10.5732/cjc.013.10133

Heng-Jun Gao, Li Xu, Yao-Jun Zhang, Min-Shan Chen

{"title":"索拉非尼联合经动脉化疗栓塞治疗肝癌合并下腔静脉肿瘤血栓患者的长期生存:2例报告并文献复习。","authors":"Heng-Jun Gao, Li Xu, Yao-Jun Zhang, Min-Shan Chen","doi":"10.5732/cjc.013.10133","DOIUrl":null,"url":null,"abstract":"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus formation in the main vasculature is extremely poor. Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC. In this study, we report two HCC patients with inferior vena cava tumor thrombus who underwent the combination treatment. The overall survival times for these two patients were 44 months and 35 months, respectively. Our report suggests that sorafenib combined with transarterial chemoembolization may be a viable choice for patients with advanced HCC even with inferior vena cava tumor thrombus. Further studies are required to verify the efficacy and safety of this combination therapy for patients with advanced HCC with inferior vena cava tumor thrombus. ","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 5","pages":"259-64"},"PeriodicalIF":0.0000,"publicationDate":"2014-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/18/cjc-33-05-259.PMC4026547.pdf","citationCount":"7","resultStr":"{\"title\":\"Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.\",\"authors\":\"Heng-Jun Gao, Li Xu, Yao-Jun Zhang, Min-Shan Chen\",\"doi\":\"10.5732/cjc.013.10133\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus formation in the main vasculature is extremely poor. Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC. In this study, we report two HCC patients with inferior vena cava tumor thrombus who underwent the combination treatment. The overall survival times for these two patients were 44 months and 35 months, respectively. Our report suggests that sorafenib combined with transarterial chemoembolization may be a viable choice for patients with advanced HCC even with inferior vena cava tumor thrombus. Further studies are required to verify the efficacy and safety of this combination therapy for patients with advanced HCC with inferior vena cava tumor thrombus. \",\"PeriodicalId\":10034,\"journal\":{\"name\":\"癌症\",\"volume\":\"33 5\",\"pages\":\"259-64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/18/cjc-33-05-259.PMC4026547.pdf\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5732/cjc.013.10133\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/12/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.013.10133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/12/11 0:00:00","PubModel":"Epub","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 7

摘要

在主要血管内形成肿瘤血栓的肝细胞癌(HCC)预后极差。索拉非尼联合经动脉化疗栓塞是晚期肝癌治疗的新途径。在这项研究中，我们报告了两例HCC合并下腔静脉肿瘤血栓的患者，他们接受了联合治疗。两例患者的总生存时间分别为44个月和35个月。我们的报告表明，索拉非尼联合经动脉化疗栓塞可能是晚期HCC患者的可行选择，即使有下腔静脉肿瘤血栓。该联合治疗晚期HCC伴下腔静脉肿瘤血栓患者的疗效和安全性有待进一步研究验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.

查看原文本刊更多论文

The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus formation in the main vasculature is extremely poor. Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC. In this study, we report two HCC patients with inferior vena cava tumor thrombus who underwent the combination treatment. The overall survival times for these two patients were 44 months and 35 months, respectively. Our report suggests that sorafenib combined with transarterial chemoembolization may be a viable choice for patients with advanced HCC even with inferior vena cava tumor thrombus. Further studies are required to verify the efficacy and safety of this combination therapy for patients with advanced HCC with inferior vena cava tumor thrombus.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

癌症 ONCOLOGY-

CiteScore

3.47

自引率

0.00%

发文量

9010

审稿时长

12 weeks

期刊介绍： In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.